Search research articles
Contact Us
Filters
Showing results (121-130 of 323) with videos related to
Page
of 33
Sort By:
British Journal of Haematology
|
February 23, 2018
Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia
Jorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
British Journal of Haematology
|
November 6, 2014
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells
Yang Cao, Zachary R Hunter, Xia Liu, et al.
British Journal of Haematology
|
January 11, 2005
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
Toshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.
Frontiers in Immunology
|
January 24, 2022
Cleavage-Mediated Regulation of Myd88 Signaling by Inflammasome-Activated Caspase-1
Monika Avbelj, Iva Hafner-Bratkovič, Duško Lainšček, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2006
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)
Scott J Rodig, Jeremy S Abramson, Geraldine S Pinkus, et al.
Seminars in Oncology
|
April 30, 2003
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations
Steven P Treon, Abigail Kelliher, Beverly Keele, et al.
Haematologica
|
May 19, 2018
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia
Jorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 2, 2011
Associated malignancies in patients with Waldenström's macroglobulinemia and their kin
Christina Hanzis, Rohit P Ojha, Zachary Hunter, et al.
Blood
|
December 25, 2013
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Zachary R Hunter, Lian Xu, Guang Yang, et al.
Blood
|
March 14, 2014
MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia
Mariateresa Fulciniti, Nicola Amodio, Rajya Lakshmi Bandi, et al.
Page
of 33
Search research articles
Search
Showing results (121-130 of 323) with videos related to
Sort By:
Page
of 33
British Journal of Haematology
|
February 23, 2018
Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia
Jorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
British Journal of Haematology
|
November 6, 2014
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells
Yang Cao, Zachary R Hunter, Xia Liu, et al.
British Journal of Haematology
|
January 11, 2005
Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application
Toshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.
Frontiers in Immunology
|
January 24, 2022
Cleavage-Mediated Regulation of Myd88 Signaling by Inflammasome-Activated Caspase-1
Monika Avbelj, Iva Hafner-Bratkovič, Duško Lainšček, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 6, 2006
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)
Scott J Rodig, Jeremy S Abramson, Geraldine S Pinkus, et al.
Seminars in Oncology
|
April 30, 2003
Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations
Steven P Treon, Abigail Kelliher, Beverly Keele, et al.
Haematologica
|
May 19, 2018
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia
Jorge J Castillo, Joshua N Gustine, Kirsten Meid, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 2, 2011
Associated malignancies in patients with Waldenström's macroglobulinemia and their kin
Christina Hanzis, Rohit P Ojha, Zachary Hunter, et al.
Blood
|
December 25, 2013
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
Zachary R Hunter, Lian Xu, Guang Yang, et al.
Blood
|
March 14, 2014
MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia
Mariateresa Fulciniti, Nicola Amodio, Rajya Lakshmi Bandi, et al.
Page
of 33